Compare GYRE & TK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GYRE | TK |
|---|---|---|
| Founded | 2002 | 1973 |
| Country | United States | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 755.7M | 822.8M |
| IPO Year | N/A | 1995 |
| Metric | GYRE | TK |
|---|---|---|
| Price | $8.01 | $9.98 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $17.00 | N/A |
| AVG Volume (30 Days) | 77.3K | ★ 546.3K |
| Earning Date | 03-16-2026 | 02-18-2026 |
| Dividend Yield | N/A | ★ 19.94% |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.04 | ★ 0.88 |
| Revenue | $107,265,000.00 | ★ $992,518,000.00 |
| Revenue This Year | $11.59 | N/A |
| Revenue Next Year | $26.31 | N/A |
| P/E Ratio | $205.16 | ★ $11.37 |
| Revenue Growth | ★ 2.13 | N/A |
| 52 Week Low | $6.11 | $5.65 |
| 52 Week High | $13.75 | $10.60 |
| Indicator | GYRE | TK |
|---|---|---|
| Relative Strength Index (RSI) | 54.30 | 61.32 |
| Support Level | $7.78 | $9.62 |
| Resistance Level | $8.17 | $9.92 |
| Average True Range (ATR) | 0.30 | 0.30 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 57.17 | 68.83 |
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
Teekay Corp Ltd provides international crude oil marine transportation and other marine services. It also offers offshore oil production, storage, and offloading services, under long-term, fixed-rate contracts. The company has two primary lines of business: Marine services and tankers. It manages these businesses for the benefit of all stakeholders. The company serves energy and utility companies, oil traders, large oil and LNG consumers, petroleum product producers, government agencies, and various other entities that depend upon marine transportation.